FDA plans infusion pump workshops
This article was originally published in The Gray Sheet
Executive Summary
CDRH Office of Compliance will encourage infusion pump manufacturers to attend FDA educational workshops designed to curb chronic product problems, said Office of Science & Engineering Laboratories Director Larry Kessler Sept. 13 during a risk management seminar in McLean, Va. The workshops follow FDA seizures of pumps from both Baxter (Colleague) and Cardinal Health (Alaris SE) and may include speakers from Kessler's office as well as the agency's human-factors engineers (1"The Gray Sheet" Sept. 4, 2006, p. 3). Kessler added that the agency's risk-based facility inspection plan is focused on pump manufacturers. "If you make infusion pumps, you can bet we're going to be visiting you," he said. The FDAer noted that firms that manufacture MRI products also are on the watch list...
You may also be interested in...
Cardinal Health Is Second Infusion Pump Maker To Be Hit By An FDA Seizure
FDA's seizure of infusion pumps made by Cardinal Health was the agency's second such enforcement action against an infusion pump manufacturer in less than a year
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.